In a bid to curb HIV, Kenya has received 21,000 starter doses of Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP).

The move marks a significant step in HIV prevention efforts as the country prepares for the first phase of rollout in early March 2026.

The injectable offers six months of protection through two doses per year, providing an alternative to daily oral PrEP.

The Ministry of Health Kenya announced that the initial distribution will target 15 high-burden counties: Mombasa, Kilifi, Machakos, Nairobi, Kajiado, Nakuru, Uasin Gishu, Kakamega, Busia, Siaya, Kisumu, Migori, Homa Bay, Kisii, and Kiambu.

Targeted rollout in high-burden counties

Speaking on Tuesday, February 17, 2026, Director General for Health Patrick Amoth clarified that Lenacapavir is intended strictly for HIV-negative individuals who are at substantial risk of infection.

“It must be stated clearly and strongly emphasised that this medicine is neither a vaccine nor a cure for HIV,” he said, urging those already receiving antiretroviral therapy to remain on lifelong treatment.

The Ministry said the rollout will be guided by national HIV data and county readiness under the Kenya PrEP Operational Plan 2025. Distribution will take place in three phases, beginning with the 15 counties, followed by another 15 counties, and finally the remaining 17 to achieve nationwide access.

Supply support and additional doses expected

The initial consignment has been supported by the Global Fund at a negotiated cost of approximately Ksh7,800 per patient per year, significantly lower than the original global price.

“Remember, at the introduction of this product, the yearly dose was about 42,000 US dollars. Now, these figures come to Ksh7,800 per patient per year. So, a great reduction in price. We are working together as part of the global community to ensure access to these innovative products,” he said.

Health officials said 12,000 continuation doses are expected by April, while the United States Government has pledged an additional 25,000 doses to support national scale-up.

Lenacapavir works by blocking key stages of the HIV life cycle, making it particularly beneficial for individuals who face challenges adhering to daily medication due to stigma, pill fatigue, or access barriers.

The government plans to integrate the drug into existing health supply systems through the Kenya Medical Supplies Authority (KEMSA).

Regulatory approval and prevention goals

The development follows a recommendation by the Pharmacy and Poisons Board for Lenacapavir registration in January 2026, which was announced by Health Cabinet Secretary Aden Duale. Kenya is among the first African countries to approve the medication in line with guidance from the World Health Organization.

According to the Ministry, Kenya’s HIV prevalence stands at 3.7 per cent, with about 1.34 million people currently receiving treatment. Officials have raised concern over new infections among young people, noting that 41 per cent occur among individuals under the age of 24.

The government said it will continue to prioritise equitable access while mobilising resources to expand prevention options as part of the broader effort to end HIV as a public health threat.